CN112830890A - Preparation method of lefenacin intermediate and lefenacin - Google Patents

Preparation method of lefenacin intermediate and lefenacin Download PDF

Info

Publication number
CN112830890A
CN112830890A CN202011396637.9A CN202011396637A CN112830890A CN 112830890 A CN112830890 A CN 112830890A CN 202011396637 A CN202011396637 A CN 202011396637A CN 112830890 A CN112830890 A CN 112830890A
Authority
CN
China
Prior art keywords
synthesizing
compound
solvent
tert
carbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011396637.9A
Other languages
Chinese (zh)
Inventor
黄才谷
黄铁强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Gusen Pharmaceutical Co ltd
Original Assignee
Shanghai Gusen Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Gusen Pharmaceutical Co ltd filed Critical Shanghai Gusen Pharmaceutical Co ltd
Priority to CN202011396637.9A priority Critical patent/CN112830890A/en
Publication of CN112830890A publication Critical patent/CN112830890A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4

Abstract

The invention relates to a synthesis method of a lefenacin intermediate, which is characterized in that piperidine-4-yl [1, 1-biphenyl ] -2-carbamate reacts with methyl carbamate (2-oxyethyl) tert-butyl ester in a solvent in the presence of a reducing agent to obtain a compound 3, wherein the chemical name of the compound 3 is as follows: biphenyl-2-ylcarbamic acid 1- [2- (tert-butoxycarbonylmethylamino) ethyl ] piperidin-4-yl ester. The lefenacin intermediate compound 3 provided by the invention has the advantages that the conditions of a synthetic line of the lefenacin are mild, the conversion rate and the selectivity are high, the reaction yield and the reaction efficiency are high, the energy consumption is low, the post-treatment is convenient, the reaction operation is simple, and the industrial production is more suitable, the lefenacin can be prepared from the intermediate in a high yield, the yield can reach more than 80%, the product purity can reach more than 99.7%, and the pharmaceutical grade is reached.

Description

Preparation method of lefenacin intermediate and lefenacin
Technical Field
The invention belongs to the technical field of drug synthesis, and discloses a lefenacin intermediate and a synthetic method of the lefenacin.
Background
Rifenacin is a long acting muscarinic antagonist which is administered by inhalation solution spray to improve pulmonary function, reduce clinical symptoms of chronic obstructive pulmonary disease and prevent further progression of the disease. On day 11/13 2017, Theravance biopharmaceutical company filed a new drug marketing application of rafenicin to the FDA in the united states for maintenance therapy of Chronic Obstructive Pulmonary Disease (COPD) in adults, approved on day 11/9 2018.
The chemical name of the rafenicin is: 1- (2- {4- [ (4-carbamoylpiperidin-1-yl) methyl ] -N-methylbenzoylamino } ethyl) piperidin-4-yl-1-yl N- ({1, 1' -biphenyl } -2-yl) carbamate, which has the formula shown in formula (1):
Figure BSA0000226494700000011
CN1930125A and CN102958916A disclose methods for preparing compounds of formula (1),
Figure BSA0000226494700000012
Figure BSA0000226494700000021
the main disadvantages of the above route are: the reaction time is long, the yield is low, the process stability is poor, the scale is difficult to be enlarged, and the biggest defect is that the heavy metal which is inevitably used in the above route is subjected to hydrogenation catalytic reduction, so that the safety risk in industrial production is greatly increased, and the use of the heavy metal causes great pollution to the environment.
In conclusion, the prior art has the disadvantages of complex reaction operation, long production period, high environmental protection pressure, greatly improved cost and unsuitability for industrial production. In the technical field of preparation of the lefenacin, a simpler and mature process route with cost advantage needs to be developed.
Disclosure of Invention
Based on the method, the invention provides the lefenacin intermediate and the preparation method thereof, and the method has the advantages of high yield, convenient operation, suitability for industrial production and the like.
The specific technical scheme is as follows:
a lefenacin intermediate, biphenyl-2-ylcarbamic acid 1- [2- (tert-butoxycarbonylmethylamino) ethyl ] piperidin-4-yl ester, or a pharmaceutically acceptable salt thereof, as shown in compound 3 or a pharmaceutically acceptable salt thereof:
Figure BSA0000226494700000022
a synthesis method of a lefenacin intermediate or a pharmaceutically acceptable salt thereof comprises the following specific steps:
in a solvent, piperidine-4-yl [1, 1-biphenyl ] -2-carbamate reacts with methyl (2-oxyethyl) tert-butyl carbamate in the presence of a reducing agent to obtain a compound 3, wherein the reaction route is as follows:
Figure BSA0000226494700000031
in some of these embodiments, the solvent comprises an organic solvent.
In some of these embodiments, the organic solvent comprises at least one of dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, ethyl acetate.
In some of these embodiments, include: adding the piperidine-4-yl [1, 1-biphenyl ] -2-carbamate, the methyl (2-oxyethyl) tert-butyl carbamate, the reducing agent and the solvent into a reaction vessel, and reacting at the temperature of 0-80 ℃ for 0.5-12 hours to obtain the compound 3.
In some of these embodiments, the molar ratio of piperidin-4-yl [1, 1-biphenyl ] -2-carbamate to methyl (2-oxyethyl) tert-butyl carbamate is 1: 1 to 1.5; and/or the molar ratio of the piperidine-4-yl [1, 1-biphenyl ] -2-carbamate to the reducing agent is 1: 2-4.
In some of these embodiments, the reducing agent comprises at least one of sodium borohydride, potassium borohydride, sodium triacetoxyborohydride, and sodium cyanoborohydride.
The invention also comprises a synthesis method of the lefenacin, which comprises the following steps:
(1) in a solvent, piperidine-4-yl [1, 1-biphenyl ] -2-carbamate reacts with methyl (2-oxyethyl) tert-butyl carbamate in the presence of a reducing agent to obtain a compound 3;
(2) dissolving the compound 3 in a solvent, and adding acid to obtain a compound 4;
(3) in a solvent, reacting the compound 4 with p-formyl benzoyl chloride in the presence of organic base or inorganic base to obtain a compound 5;
(4) and reacting the compound 5 with isopiperidine formamide in the presence of a reducing agent in an organic solvent to obtain the ralfinacin 1.
The reaction route is as follows:
Figure BSA0000226494700000041
in some of these embodiments, the solvent of step (1) comprises an organic solvent.
In some of the embodiments, the organic solvent in step (1) comprises at least one of dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, and ethyl acetate.
In some of these embodiments, step (1) comprises: adding the piperidine-4-yl [1, 1-biphenyl ] -2-carbamate, the methyl (2-oxyethyl) tert-butyl carbamate, the reducing agent and the solvent into a reaction vessel, and reacting at the temperature of 0-80 ℃ for 0.5-12 hours to obtain the compound 3.
In some of these embodiments, the molar ratio of piperidin-4-yl [1, 1-biphenyl ] -2-carbamate to methyl (2-oxyethyl) tert-butyl carbamate of step (1) is 1: 1 to 1.5; and/or the molar ratio of the piperidine-4-yl [1, 1-biphenyl ] -2-carbamate to the reducing agent is 1: 2-4.
In some of these embodiments, the reducing agent in step (1) is at least one selected from the group consisting of sodium borohydride, potassium borohydride, sodium triacetoxyborohydride, and sodium cyanoborohydride.
In some of these embodiments, the solvent of step (2) comprises an organic solvent.
In some of these embodiments, the organic solvent of step (2) comprises at least one of dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, ethyl acetate, 1, 4-dioxane.
In some embodiments, the reaction temperature in step (2) is 0 to 80 ℃; and/or the reaction time in the step (2) is 0.5-3 h.
In some of these embodiments, the acid of step (2) comprises at least one of trifluoroacetic acid, hydrochloric acid gas.
In some embodiments, the mass-to-volume ratio of the compound 3 to the solvent in the step (2) is 1: 1-10; and/or the mass volume ratio of the compound 3 to the acid in the step (2) is 1: 1-3.
In some of these embodiments, the solvent of step (3) comprises an organic solvent.
In some of the embodiments, the organic solvent in step (3) comprises at least one of tetrahydrofuran, dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, and ethyl acetate.
In some of the embodiments, the reaction temperature in the step (3) is 0 to 35 ℃; and/or the reaction time in the step (3) is 10-60 min.
In some embodiments, the organic base in step (3) comprises at least one of N, N-diisopropylethylamine, triethylamine, ammonia water, ethylenediamine and pyridine, and the inorganic base comprises at least one of sodium hydroxide, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
In some embodiments, the reducing agent in step (4) comprises at least one of sodium borohydride, potassium borohydride, sodium triacetoxyborohydride, and sodium cyanoborohydride.
The lefenacin has the following advantages and beneficial effects:
(1) the invention has high reaction conversion rate and selectivity, greatly improves the reaction yield and reduces the cost;
(2) the method has the advantages of high reaction efficiency, low reaction temperature, low energy consumption and simple reaction operation, and multiple steps are carried out at normal temperature;
(3) the synthesis route of the invention has mild conditions and convenient post-treatment, and is more suitable for industrial production.
The reagents and materials involved in the invention are all commercially available.
Detailed Description
The synthesis method of rafenine of the present invention is described in further detail below with reference to specific examples.
EXAMPLE 1 Synthesis of Compound 3
Figure BSA0000226494700000061
Piperidine-4-yl [1, 1-biphenyl]-2-Carbamate (5.04g, 17.0mmol) and NaHB (OAc)3(7.21g, 34.0mmol) was added successively to a 100mL flask containing the product methyl (2-oxyethyl) tert-butyl carbamate (3.24g, 18.7mmol) in DCM (60 mL), the reaction was stirred at room temperature for 1.5h, then 1N HCl (20mL) was added and stirred vigorously. After standing, three layers appeared, and the aqueous layer was separated and discarded. The organic layer was washed with 1N NaOH (20mL) and saturated brine (20mL), dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure to give a pale yellow oily liquid, which was purified by flash column to give the desired product 3(7.63g, 98% yield, 99% HPLC purity).
Ms m/z：[M+H+]454.4；1H-NMR(500MHz，CDCl3)：δ8.12(1H，s)，7.38～7.11(8H，m)，6.58(1H，m)，4.73(1H，m)，3.31(2H，m)，2.96(3H，s)，2.73～1.67(10H，m)，1.45(9H，s)。
Replacing DCM in example 1 with one or more of chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether and ethyl acetate; the NaHB (OAc)3 is replaced by other reducing agents (sodium borohydride, potassium borohydride and sodium cyanoborohydride), and the compound 3 can be prepared smoothly with the yield of 65-95%.
EXAMPLE 2 Synthesis of Compound 4
Figure BSA0000226494700000062
Dissolving the intermediate compound 3 prepared in the embodiment 1 in DCM with the volume 4 times that of the intermediate compound, slowly and dropwise adding TFA with about solvent amount 1/4, stirring for about 2 hours at 10-15 ℃, supplementing TFA with about solvent amount 1/8, reacting for 0.5 hour, completely reacting, adjusting pH to be alkalescent by triethylamine or sodium bicarbonate aqueous solution, washing with water, separating liquid, drying by spinning, and purifying by a fast adsorption column to obtain the target product 4. Quantitative yield, HPLC purity 99%.
Ms m/z：[M+H+]354.3；1H-NMR(500MHz，CDCl3)：δ8.07(1H，s)，7.49～7.11(8H，m)，6.60(1H，m)，4.77(1H，m)，3.03(2H，m)，2.73(4H，m)，2.71(3H，s)，2.37～1.70(6H，m)。
The DCM in the embodiment 2 is replaced by any one or more of chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, ethyl acetate and 1, 4-dioxane; the TFA is replaced by hydrochloric acid gas, so that 4 can be prepared successfully, and the yield is 65-95%.
EXAMPLE 3 Synthesis of Compound 5
Figure BSA0000226494700000071
Adding p-aldehyde benzoic acid (5g, 33.3mmol) into 30ml of toluene, adding 20ml of thionyl chloride, reacting for 3 hours at 80 ℃, and then spin-drying to obtain p-aldehyde benzoyl chloride for later use.
To the compound 4 obtained in the previous example 2 were added 40ml of THF, 25ml of aqueous solution, 2.65g of Na2CO3Adding 3.09g of p-formyl benzoyl chloride at O ℃, stirring at room temperature for reaction for 20min, adding 80ml of DCM for dilution after the reaction is finished, separating liquid, taking an organic phase, washing the organic phase with 1M hydrochloric acid, then washing with 1M NaOH solution and saturated salt solution, and then spin-drying to obtain 7.35g of white solid, wherein the yield is 90%, and the HPLC purity is 99%.
Ms m/z：[M+H+]485.6；1H-NMR(500MHz，CDCl3)：δ10.05(1H，s)，8.10(1H，s)，7.93～7.21(12H，m)，6.58(1H，m)，4.72(1H，m)，3.68～1.61(16H，m)。
The THF in the embodiment 3 is replaced by any one or more of water, dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether and ethyl acetate; the sodium carbonate is replaced by any one or more of sodium hydroxide, potassium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine and N, N-diisopropylethylamine, and the compound 5 can also be successfully prepared, with the yield of 28-90%.
Example 4 Synthesis of Rafenacin 1
Figure BSA0000226494700000081
To a three-necked flask were added in this order isopiperidinecarboxamide 8(2.30g, 18.0mmol), acetic acid 5mL, sodium sulfate 2.50g, and isopropanol 10 mL. The reaction mixture was cooled to 0-10 ℃ with an ice bath and a solution of product compound 5(4.32g, 8.9mmol) in IPA (10mL) was added slowly. The reaction was stirred at room temperature for 2 hours and then cooled to 0-10 ℃. Adding NaHB (OAc) in portions3(5.41g, 25.5mmol) and the mixture was stirred at room temperature for 16 h. Then concentrated under reduced pressure to a volume of about 50 mL. The mixture was acidified to pH 3 with 1N HCl (200 mL). The resulting mixture was stirred at room temperature for 1 hour, then extracted with DCM (3 × 100 mL). The aqueous phase was cooled to 0-5 ℃ with an ice bath and adjusted to pH 10 by the addition of 50% aqueous sodium hydroxide. Then extracted with isopropyl acetate (3 × 100mL), washed with water (100mL), brine (2 × 50mL) and the organic layers combined, dried over anhydrous sodium sulfate, filtered and concentrated to give 4.54g of the title compound 1 rafenicin as a white solid (HPLC purity: 99.7%, yield 85%) after purification by flash column.
Ms m/z：[M+H+]598.7；1H-NMR(500MHz，DMSO-d6)：δ8.60(1H，s)，7.41～7.16(14H，m)，6.67(1H，m)，4.41(1H，m)，3.49～3.21(7H，m)，2.90～2.79(5H，m)，2.49～1.51(14H，m)。
The NaHB (OAc) in example 1 was added3Any one or more of other reducing agents such as sodium borohydride, potassium borohydride and sodium cyanoborohydride can be replaced, the compound 1 can be prepared smoothly, and the yield is 70-80%.
Comparative example Synthesis of Rifenacin 1 (see CN1930125A)
The synthetic route is as follows:
Figure BSA0000226494700000091
step 1) Synthesis of Compound 9
Compound 11(20.7g, 100mmol) and 2(25.1g, 84.7mmol) were dissolved in methanol (200ml), and NaHB (OAc) was added thereto under stirring3(21.2g, 100 mmol). The reaction mixture was stirred at room temperature for 12 hours and quenched with 2M hydrochloric acid and the acid and solvent were removed under reduced pressure. The residue was dissolved in ethyl acetate (200mL), washed with saturated aqueous sodium bicarbonate (100mL) and brine (50mL), dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to give the crude product. Subjecting the crude product to column purification chromatography (50-90% EtOAc/hexane) to obtain biphenyl-2-ylcarbamic acid 1- [2- (benzyloxycarbonyl) -methylamino) ethyl]Piperidin-4-yl ester 9 oil 32.1 g. (HPLC purity: 90%, yield 70%)
Step 2) Synthesis of Compound 4
The biphenyl-2-ylcarbamic acid 1- [2- (benzyloxycarbonylmethyl) amino) ethyl ] piperidin-4-yl ester 9 oil obtained in the previous step was dissolved in methanol (100mL) and palladium on carbon (5g, 10 wt.%, dry basis) was added. The reaction was stirred under hydrogen (30psi) for 12 hours, then filtered through celite, washed with methanol, and the solvent was distilled off under reduced pressure to give the objective compound 4(10.2g, yield 44%, HPLC purity: 90%).
Step 3) Synthesis of Compound 5
A1L three-necked flask was charged with 4-carboxybenzaldehyde (4.77g, 31.8mmol), EDAC (6.65g, 34.7mmol), HOBT (4.30g, 31.8mmol) and DCM (200 mL). After dissolution, a solution containing product 4(11.2g, 31.8mmol) in DCM (100mL) was added slowly. After stirring at room temperature for about 16 hours, the reaction mixture was washed with water (1X 100mL), 1N HCl (5X 60mL), 1N NaOH (1X 100mL) and saturated brine (1X 50mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain 16.7g of the title compound 5 (yield: 92%; purity by HPLC 85%).
Step 4) Synthesis of Compound 1
To a three-necked flask was added isopiperidinecarboxamide 8(2.31g, 18.0mmol), acetic acid (5mL), sodium sulfate (2.5g), and isopropanol (10 mL). The reaction mixture was cooled to 0-10 ℃ with an ice bath and a solution of product 5(4.3g, 8.9mmol) in IPA (10mL) was added slowly. The reaction was stirred at room temperature for 2 hours and then cooled to 0-10 ℃. NaHB (OAc)3(5.4g, 25.5mmol) was added in portions and the mixture was stirred at room temperature for 16 h. Then concentrated under reduced pressure to a volume of about 50 mL. The mixture was acidified to pH 3 with 1N HCl (200 mL). The resulting mixture was stirred at room temperature for 1 hour, then extracted with DCM (3 × 100 mL). The aqueous phase was cooled to 0-5 ℃ with an ice bath and adjusted to pH 10 by the addition of 50% aqueous sodium hydroxide. Then extracted with isopropyl acetate (3 × 100mL), washed with water (100mL), brine (2 × 50mL) and the organic layers combined, dried over anhydrous sodium sulfate, filtered and concentrated to give 4.6g of the title compound 1 rafenicin as a white solid (HPLC purity: 95%, yield 82%) after purification by flash column.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims (19)

1. A lefenacin intermediate characterized by the chemical name: biphenyl-2-ylcarbamic acid 1- [2- (tert-butoxycarbonylmethylamino) ethyl ] piperidin-4-yl ester or a pharmaceutically acceptable salt thereof, a compound represented by formula (3) or a pharmaceutically acceptable salt thereof:
Figure FSA0000226494690000011
2. a method for synthesizing a lefenacin intermediate or a pharmaceutically acceptable salt thereof, which is characterized by comprising the following steps:
in a solvent, piperidine-4-yl [1, 1-biphenyl ] -2-carbamate reacts with methyl (2-oxyethyl) tert-butyl carbamate in the presence of a reducing agent to obtain a compound (3), wherein the reaction route is as follows:
Figure FSA0000226494690000012
3. the method of synthesizing a rafenicine intermediate or a pharmaceutically acceptable salt thereof according to claim 2, wherein the solvent comprises an organic solvent.
4. The method of synthesizing a rafenicin intermediate or pharmaceutically acceptable salt thereof as claimed in claim 3 wherein the organic solvent comprises at least one of dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, ethyl acetate.
5. A method of synthesizing the rafenicine intermediate or a pharmaceutically acceptable salt thereof according to any one of claims 2 to 4, comprising: adding the piperidine-4-yl [1, 1-biphenyl ] -2-carbamate, the methyl (2-oxyethyl) tert-butyl carbamate, the reducing agent and the solvent into a reaction vessel, and reacting at the temperature of 0-80 ℃ for 0.5-12 hours to obtain the compound (3).
6. The method for synthesizing the rafenicin intermediate or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5, wherein the molar ratio of the piperidin-4-yl [1, 1-biphenyl ] -2-carbamate to the methyl (2-oxyethyl) tert-butyl carbamate is 1: 1 to 1.5; and/or the molar ratio of the piperidine-4-yl [1, 1-biphenyl ] -2-carbamate to the reducing agent is 1: 2-4.
7. The method for synthesizing the ralfinacin intermediate or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 6, wherein the reducing agent comprises at least one of sodium borohydride, potassium borohydride, sodium triacetoxyborohydride and sodium cyanoborohydride.
8. A synthesis method of lefenacin is characterized by comprising the following steps:
(1) in a solvent, piperidine-4-yl [1, 1-biphenyl ] -2-carbamate reacts with methyl (2-oxyethyl) tert-butyl carbamate in the presence of a reducing agent to obtain a compound (3);
(2) dissolving the compound (3) in a solvent, and adding acid to obtain a compound (4);
(3) in a solvent, reacting the compound (4) with p-formyl benzoyl chloride in the presence of organic base or inorganic base to obtain the compound (5);
(4) reacting the compound (5) with isopiperidine formamide in the presence of a reducing agent in an organic solvent to obtain the ralfinacin (1);
the reaction route is as follows:
Figure FSA0000226494690000021
Figure FSA0000226494690000031
9. the method for synthesizing rafenine according to claim 8, wherein the method for synthesizing the chemical (3) is the same as the method for synthesizing the compound (3) according to any one of claims 2 to 7.
10. The method of synthesizing rafenisin of claim 8, wherein the solvent of step (2) comprises an organic solvent.
11. The method of synthesizing rafenisin of claim 10, wherein the organic solvent of step (2) comprises at least one of dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, ethyl acetate, 1, 4-dioxane.
12. The method for synthesizing rafenine according to claim 8, wherein the reaction temperature in the step (2) is 0-80 ℃; and/or the reaction time in the step (2) is 0.5-3 h.
13. The method of synthesizing rafenisin of claim 8, wherein the acid of step (2) comprises at least one of trifluoroacetic acid and hydrochloric acid gas.
14. The method for synthesizing the rafenine according to claim 8, wherein the mass-to-volume ratio of the compound (3) to the solvent in the step (2) is 1: 1-10; and/or the mass volume ratio of the compound (3) to the acid in the step (2) is 1: 1-3.
15. The method of synthesizing rafenisin of claim 8, wherein the solvent of step (3) comprises an organic solvent.
16. The method of synthesizing rafenisin of claim 8, wherein the organic solvent of step (3) comprises at least one of tetrahydrofuran, dichloromethane, chloroform, toluene, isopropanol, methanol, ethanol, methyl tert-butyl ether, and ethyl acetate.
17. The method for synthesizing rafenine according to claim 8, wherein the reaction temperature in step (3) is 0-35 ℃; and/or the reaction time in the step (3) is 10-60 min.
18. The method for synthesizing rafenine according to claim 8, wherein the organic base in step (3) comprises at least one of N, N-diisopropylethylamine, triethylamine, ammonia water, ethylenediamine and pyridine, and the inorganic base comprises at least one of sodium hydroxide, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
19. The method for synthesizing rafenicin according to claim 8, wherein the reducing agent in step (4) comprises at least one of sodium borohydride, potassium borohydride, sodium triacetoxyborohydride, and sodium cyanoborohydride.
CN202011396637.9A 2020-12-03 2020-12-03 Preparation method of lefenacin intermediate and lefenacin Pending CN112830890A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011396637.9A CN112830890A (en) 2020-12-03 2020-12-03 Preparation method of lefenacin intermediate and lefenacin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011396637.9A CN112830890A (en) 2020-12-03 2020-12-03 Preparation method of lefenacin intermediate and lefenacin

Publications (1)

Publication Number Publication Date
CN112830890A true CN112830890A (en) 2021-05-25

Family

ID=75923439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011396637.9A Pending CN112830890A (en) 2020-12-03 2020-12-03 Preparation method of lefenacin intermediate and lefenacin

Country Status (1)

Country Link
CN (1) CN112830890A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110526859A (en) * 2019-08-07 2019-12-03 山东百诺医药股份有限公司 A kind of preparation method of Rui Weina new intermediate and preparation method thereof and Rui Weinaxin
IN202011029286A (en) * 2020-07-10 2020-10-09 Mankind Pharma Ltd.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110526859A (en) * 2019-08-07 2019-12-03 山东百诺医药股份有限公司 A kind of preparation method of Rui Weina new intermediate and preparation method thereof and Rui Weinaxin
IN202011029286A (en) * 2020-07-10 2020-10-09 Mankind Pharma Ltd.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin

Similar Documents

Publication Publication Date Title
CN108314639B (en) Compound (E) -3-(1- methylpyrrolidin- 2- yl)-acrylic acid hydrochloride and synthetic method
CN110526859B (en) Revinanexin intermediate, preparation method thereof and preparation method of Revinanexin
CN108586389B (en) Method for synthesizing Carilazine
CN101220007B (en) Method for producing repaglinide
JP5457555B2 (en) Method for producing tricyclic derivative
CN112062767B (en) Preparation method and intermediate of rumepilone
CN109206317B (en) Preparation process of amantadine nitrate derivative
CN113121416A (en) Preparation method of lefenacin
CN114478690B (en) Preparation method of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane derivative
CN109879817A (en) The preparation method of mesosulfuron
CN100591649C (en) Method of preparing R-(+)-3-chlorophenylpropanol
CA2810393A1 (en) Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament
CN112830890A (en) Preparation method of lefenacin intermediate and lefenacin
CN114573500A (en) Preparation method of lefenacin intermediate
CN107056681B (en) A kind of support method replaces the preparation method of cloth intermediate
CN106699604B (en) One seed sand library is than bent and its intermediate preparation method
CN105745191B (en) A kind of preparation method of silodosin and its intermediate
JP2002524550A (en) Method for producing N-substituted hydroxycycloalkylamine derivative
CN106946724B (en) The synthetic method of monoamine base inhibitor class intermediate 2- acetylaminohydroxyphenylarsonic acid 2- benzyl malonic acid mono ethyl ester
CN103922986B (en) Vildagliptin, vildagliptin analogues and vildagliptin intermediate, and preparation methods of three and application
JP2010535185A (en) Method for producing alfuzosin hydrochloride
CN109574860B (en) Method for preparing vilanterol
CN102807516A (en) Intermediate in amisulpride and method for preparing amisulpride by using intermediate
CN109320510B (en) Preparation method of Maropitan free base
CN102336676A (en) New preparation method of dopexamine hydrochloride by ArCHR protection strategy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
DD01 Delivery of document by public notice

Addressee: He Huimin

Document name: Notification of eligibility

DD01 Delivery of document by public notice
RJ01 Rejection of invention patent application after publication

Application publication date: 20210525

RJ01 Rejection of invention patent application after publication